Personalis Secures Medicare Coverage for Lung Cancer Monitoring
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Should l Buy PSNL?
Source: Newsfilter
- Medicare Coverage Expansion: Personalis announced that its NeXT Personal molecular residual disease (MRD) test has secured Medicare coverage, aimed at enhancing monitoring for approximately 230,000 newly diagnosed lung cancer patients, thereby improving their treatment confidence and management capabilities.
- Clinical Validation Support: This coverage decision is grounded in clinical evidence generated through collaboration with TRACERx, demonstrating NeXT Personal's ability to accurately identify residual disease, further solidifying its clinical efficacy in lung cancer monitoring.
- Technological Advantage: NeXT Personal leverages whole-genome sequencing and advanced noise-suppression technology to track up to 1,800 mutations, providing a reliable tool for recurrence and residual disease monitoring, assisting clinicians in effective management where ctDNA detection is challenging.
- Market Growth Catalyst: CEO Chris Hall stated that this Medicare coverage not only broadens patient access to NeXT Personal but also serves as a catalyst for the company's continued growth, highlighting its strategic execution in the cancer management sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.160
Low
10.00
Averages
11.17
High
12.00
Current: 8.160
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lightspeed Acquires Significant Stake in Kodiak AI
- Stake Acquisition: Lightspeed Management Company purchased 7,340,475 shares of Kodiak AI in Q4 2026 for approximately $80.16 million, representing 5.74% of the fund's 13F reportable AUM, indicating strong conviction in the company's future prospects.
- Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, reflecting a 5.66% increase since its public debut in September 2025, outperforming the S&P 500 by 1.51 percentage points during the same period, showcasing market confidence in its growth.
- Company Overview: Kodiak AI specializes in autonomous driving solutions for commercial and defense applications, leveraging a proprietary multi-sensor architecture to deliver scalable AI navigation in complex environments, targeting commercial transport, defense contractors, and industrial fleet operators.
- Investment Outlook: Despite being a smaller player in the self-driving sector, Kodiak AI has garnered industry attention, with Northland naming it a top pick for 2026 with a price target of $17, reflecting expectations for significant growth potential in the autonomous trucking industry.
See More
Lightspeed Acquires Shares of Kodiak AI
- New Investment Move: Lightspeed acquired 7,340,475 shares of Kodiak AI in Q4 2026, with an estimated transaction value of $80.16 million, reflecting strong confidence in the company, especially given its public listing just six months prior.
- Asset Management Shift: This transaction increased Lightspeed's 13F reportable assets under management (AUM) by 5.74%, highlighting its commitment to Kodiak AI and enhancing its market position in the autonomous driving sector.
- Strong Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, up 5.66% since its September 2025 IPO, outperforming the S&P 500 by 1.51 percentage points, indicating its appeal in a competitive market.
- Industry Outlook Analysis: Kodiak AI focuses on autonomous driving solutions for commercial and defense applications, and while it is a relatively small player, its long-term success will largely depend on the development of the autonomous trucking industry, particularly the adoption of the 'Driving as a Service' model.
See More
Personalis, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Clinical Test Growth: In Q4 2025, Personalis delivered 6,183 clinical tests, representing a 41% sequential growth over Q3 2025 and a 329% year-over-year increase, demonstrating the company's leadership in ultrasensitive MRD testing and robust market demand recovery.
- Revenue and Outlook: The company reported $17.3 million in revenue for Q4, a modest 3% year-over-year increase, while projecting total revenue for 2026 to reach between $78 million and $80 million, reflecting confidence in future growth and strategic market expansion.
- Strategic Expansion: The partnership with Tempus has been strengthened with new coverage for colorectal cancer, and clinical test volumes are expected to reach 43,000 to 45,000 in 2026, indicating a year-over-year growth rate of approximately 170%, which will further solidify market share.
- Financial Health: At the end of 2025, cash and short-term investments totaled $240 million, and while a net loss of approximately $105 million is anticipated for 2026, the company maintains strong cash flow to support future R&D and market expansion.
See More
Personalis (PSNL) Q4 2025 Earnings Call Transcript
See More
Personalis Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Personalis reported a Q4 GAAP EPS of -$0.26, beating expectations by $0.03, indicating an improvement in financial performance despite remaining in the red.
- Revenue Growth: Q4 revenue reached $17.35 million, up 3.3% year-over-year, exceeding market expectations by $0.23 million, demonstrating enhanced competitiveness in the market.
- Surge in Clinical Tests: Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests, with a nearly 400% increase for the full year to 16,233 tests, reflecting strong demand for clinical services.
- Future Guidance: Full-year 2026 revenue guidance is set at $78 to $80 million, below the consensus of $81.68 million, although clinical revenue is expected to grow approximately 5x, indicating a cautious outlook on future growth.
See More
Personalis to Announce Q4 Earnings on February 26th
- Earnings Announcement Date: Personalis (PSNL) is set to release its Q4 earnings report on February 26th after market close, with market participants keenly awaiting the results that could impact stock performance.
- EPS Expectations: The consensus EPS estimate stands at -$0.28, reflecting a 21.7% year-over-year decline, indicating challenges in profitability that may affect investor sentiment.
- Revenue Forecast Adjustments: The anticipated revenue for Q4 is $17.12 million, representing a modest 1.9% year-over-year increase, despite one upward revision and two downward adjustments, suggesting cautious market sentiment regarding the company's growth.
- Future Revenue Guidance: Personalis projects FY 2025 revenue between $69 million and $70 million, demonstrating confidence in future growth prospects, although current earnings data may lead to short-term volatility.
See More
Lightspeed Acquires Significant Stake in Kodiak AI
- Stake Acquisition: Lightspeed Management Company purchased 7,340,475 shares of Kodiak AI in Q4 2026 for approximately $80.16 million, representing 5.74% of the fund's 13F reportable AUM, indicating strong conviction in the company's future prospects.
- Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, reflecting a 5.66% increase since its public debut in September 2025, outperforming the S&P 500 by 1.51 percentage points during the same period, showcasing market confidence in its growth.
- Company Overview: Kodiak AI specializes in autonomous driving solutions for commercial and defense applications, leveraging a proprietary multi-sensor architecture to deliver scalable AI navigation in complex environments, targeting commercial transport, defense contractors, and industrial fleet operators.
- Investment Outlook: Despite being a smaller player in the self-driving sector, Kodiak AI has garnered industry attention, with Northland naming it a top pick for 2026 with a price target of $17, reflecting expectations for significant growth potential in the autonomous trucking industry.
See More
Lightspeed Acquires Shares of Kodiak AI
- New Investment Move: Lightspeed acquired 7,340,475 shares of Kodiak AI in Q4 2026, with an estimated transaction value of $80.16 million, reflecting strong confidence in the company, especially given its public listing just six months prior.
- Asset Management Shift: This transaction increased Lightspeed's 13F reportable assets under management (AUM) by 5.74%, highlighting its commitment to Kodiak AI and enhancing its market position in the autonomous driving sector.
- Strong Market Performance: As of February 27, 2026, Kodiak AI's stock price stood at $8.40, up 5.66% since its September 2025 IPO, outperforming the S&P 500 by 1.51 percentage points, indicating its appeal in a competitive market.
- Industry Outlook Analysis: Kodiak AI focuses on autonomous driving solutions for commercial and defense applications, and while it is a relatively small player, its long-term success will largely depend on the development of the autonomous trucking industry, particularly the adoption of the 'Driving as a Service' model.
See More
Personalis, Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Clinical Test Growth: In Q4 2025, Personalis delivered 6,183 clinical tests, representing a 41% sequential growth over Q3 2025 and a 329% year-over-year increase, demonstrating the company's leadership in ultrasensitive MRD testing and robust market demand recovery.
- Revenue and Outlook: The company reported $17.3 million in revenue for Q4, a modest 3% year-over-year increase, while projecting total revenue for 2026 to reach between $78 million and $80 million, reflecting confidence in future growth and strategic market expansion.
- Strategic Expansion: The partnership with Tempus has been strengthened with new coverage for colorectal cancer, and clinical test volumes are expected to reach 43,000 to 45,000 in 2026, indicating a year-over-year growth rate of approximately 170%, which will further solidify market share.
- Financial Health: At the end of 2025, cash and short-term investments totaled $240 million, and while a net loss of approximately $105 million is anticipated for 2026, the company maintains strong cash flow to support future R&D and market expansion.
See More
Personalis (PSNL) Q4 2025 Earnings Call Transcript
See More
Personalis Q4 Earnings Beat Expectations with Revenue Growth
- Earnings Highlights: Personalis reported a Q4 GAAP EPS of -$0.26, beating expectations by $0.03, indicating an improvement in financial performance despite remaining in the red.
- Revenue Growth: Q4 revenue reached $17.35 million, up 3.3% year-over-year, exceeding market expectations by $0.23 million, demonstrating enhanced competitiveness in the market.
- Surge in Clinical Tests: Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests, with a nearly 400% increase for the full year to 16,233 tests, reflecting strong demand for clinical services.
- Future Guidance: Full-year 2026 revenue guidance is set at $78 to $80 million, below the consensus of $81.68 million, although clinical revenue is expected to grow approximately 5x, indicating a cautious outlook on future growth.
See More
Personalis to Announce Q4 Earnings on February 26th
- Earnings Announcement Date: Personalis (PSNL) is set to release its Q4 earnings report on February 26th after market close, with market participants keenly awaiting the results that could impact stock performance.
- EPS Expectations: The consensus EPS estimate stands at -$0.28, reflecting a 21.7% year-over-year decline, indicating challenges in profitability that may affect investor sentiment.
- Revenue Forecast Adjustments: The anticipated revenue for Q4 is $17.12 million, representing a modest 1.9% year-over-year increase, despite one upward revision and two downward adjustments, suggesting cautious market sentiment regarding the company's growth.
- Future Revenue Guidance: Personalis projects FY 2025 revenue between $69 million and $70 million, demonstrating confidence in future growth prospects, although current earnings data may lead to short-term volatility.
See More
